BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31271959)

  • 1. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
    Cui S; Wang Y; Wang Y; Tang X; Ren X; Zhang L; Xu Y; Zhang Z; Zhang ZM; Lu X; Ding K
    Eur J Med Chem; 2019 Oct; 179():470-482. PubMed ID: 31271959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models.
    Zou J; Zhang Z; Xu F; Cui S; Qi C; Luo J; Wang Z; Lu X; Tu Z; Ren X; Song L; Ding K
    J Drug Target; 2019 Apr; 27(4):442-450. PubMed ID: 30301369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W; Zhang L; Lv F; Moccia M; Carlomagno F; Landry C; Santoro M; Gosselet F; Frett B; Li HY
    Eur J Med Chem; 2021 Apr; 216():113265. PubMed ID: 33652352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
    Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human.
    Bernard-Gauthier V; Bailey JJ; Mossine AV; Lindner S; Vomacka L; Aliaga A; Shao X; Quesada CA; Sherman P; Mahringer A; Kostikov A; Grand'Maison M; Rosa-Neto P; Soucy JP; Thiel A; Kaplan DR; Fricker G; Wängler B; Bartenstein P; Schirrmacher R; Scott PJH
    J Med Chem; 2017 Aug; 60(16):6897-6910. PubMed ID: 28696690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
    Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
    Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
    Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines.
    Kamal A; Ramakrishna G; Raju P; Rao AV; Viswanath A; Nayak VL; Ramakrishna S
    Eur J Med Chem; 2011 Jun; 46(6):2427-35. PubMed ID: 21481986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and Structure-Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors.
    Duan Y; Wang J; Zhu S; Tu ZC; Zhang Z; Chan S; Ding K
    Eur J Med Chem; 2020 Oct; 203():112552. PubMed ID: 32702585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
    Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
    Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
    Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
    Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
    J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
    Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.